Representative images of trametinib (75 nM), VS4718 (250 nM) phenotypes versus DMSO (0.1% (v/v)) are shown for GBM stem cells belonging to the mesenchymal subtype, GCGR-E21 and -E57 cells, indicating increased cell spreading upon trametinib treatment (Figure 4C). This evidence concerns the gene GCGR and glioblastoma.